יתרות מזומנים למניה RedHill Biopharma Ltd (RDHL)

סמל תאגידי ולוגו של RedHill Biopharma Ltd (RDHL)

RedHill Biopharma generates revenue from the sale of gastrointestinal therapies, betting on the drug Talicia and oncology research. Partnerships with global distributors help the company scale distribution and advance joint development projects. The cash per share allows for a real-time assessment of the issuer's solvency, where the value 0.58 represents the current metric. The commercial growth stage and the expansion of indications for existing drugs will serve as key revenue drivers.

RedHill Biopharma (RDHL) - מזומנים למניה מ-04.07.2022 עד 20.11.2026

פילוחים אנליטיים של חברת RedHill Biopharma

- ציטוטים ותחזית אנליסטים:
- פרטי פוזיציית מזומנים ותזרימי מזומנים:
ניתוח מקיף של החברה:RedHill Biopharma Ltd. (RDHL)
מוצר המיוצר על ידי RedHill Biopharma Ltd.

RedHill Biopharma's independence from macro cycles requires significant reserves to fund clinical trials and drug commercialization. This indicator measures the volume of liquid assets per common share. An increase in this metric confirms strengthening financial stability and a reduction in debt risks. It is critical for investors to maintain a balance between capital security and capital efficiency. By analyzing the cash position per share, one can assess the issuer's real margin of safety.